SML3710
Linaclotide
≥95% (HPLC)
别名:
CCEFCCNPACTGCF-OH cyclo(1-6),(2-10),(5-13)-tris(disulfide), Cys-Cys-Glu-Tyr-Cys-Cys-Asn-Pro-Ala-Cys-Thr-Gly-Cys-Tyr-OH cyclo(1-6),(2-10),(5-13)-tris(disulfide), L-Cysteinyl-L-cysteinyl-L-α-glutamyl-L-tyrosyl-L-cysteinyl-L-cysteinyl-L-asparaginyl-L-prolyl-L-alanyl-L-cysteinyl-L-threonylglycyl-L-cysteinyl-L-tyrosine-OH cyclo(1-6),(2-10),(5-13)-tris(disulfide)
登录查看公司和协议定价
所有图片(1)
About This Item
推荐产品
品質等級
化驗
≥95% (HPLC)
形狀
(Powder or Lyophilized powder or film)
儲存條件
desiccated
顏色
white to off-white
儲存溫度
-10 to -25°C
生化／生理作用
Linaclotide is an orally active guanylate cyclase-C (GC-C) agonist that competes against bacterial STa enterotoxin binding to intestinal mucosal membranes from wild-type, but not GC-C null, mice (Ki = 16.4 nM). Linaclotide stimulates fluid secretion, upregulates cGMP accumulation in the intestinal lumen (5 μg/100 μL via injection into surgically ligated intestinal loops), and significantly increases the rate of gastrointestinal transit when administered orally in mice in vivo (100 μg/kg p.o.).
注意
Hygroscopic
訊號詞
Warning
危險聲明
危險分類
Acute Tox. 4 Oral
儲存類別代碼
11 - Combustible Solids
水污染物質分類（WGK）
WGK 3
閃點（°F）
Not applicable
閃點（°C）
Not applicable
John Cuppoletti et al.
BMC pharmacology, 12, 3-3 (2012-05-05)
Linaclotide has been proposed as a treatment for the same gastrointestinal indications for which lubiprostone has been approved, chronic idiopathic constipation and irritable bowel syndrome with constipation. Stressors damage the epithelial cell barrier and cellular homeostasis leading to loss of
Alexander P Bryant et al.
Life sciences, 86(19-20), 760-765 (2010-03-24)
Linaclotide is an orally administered 14-amino acid peptide being developed for the treatment of constipation-predominant irritable bowel syndrome (IBS-C) and chronic constipation. We determined the stability of linaclotide in the intestine, measured the oral bioavailability, and investigated whether the pharmacodynamic
Robert W Busby et al.
European journal of pharmacology, 649(1-3), 328-335 (2010-09-25)
Linaclotide is a first-in-class, orally administered 14-amino acid peptide that is in development for the treatment of irritable bowel syndrome with constipation and chronic constipation. We have characterized the solution structure of linaclotide, the in vitro binding and agonist activity
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门